Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that it has raised $106.5 million to support pivotal-stage development of its lead […]
Royal DSM, a global science-based leader in health, nutrition and bioscience, announces that it has entered into exclusive negotiations with Adare Pharma Solutions in order to acquire Adare Biome, a pioneer in the development and […]
Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced the publication of Phase 2 study results from its lead program, VE303, in […]
Microbiotica, a leader in discovering and developing microbiome-based therapeutics and biomarkers, announces it has entered into a clinical trial collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA). Under the terms of the agreement, […]
Metagen Therapeutics (President and CEO: Taku Nakahara, PhD; Headquarters: Yamagata, Japan; hereinafter referred to as “MGTx”) has announced a JPY 1.1B investment in its Series A funding as of April, 2023. MGTx has been accelerating […]
In a step forward for genetic engineering and synthetic biology, researchers have modified a strain of Escherichia coli bacteria to be immune to natural viral infections while also minimizing the potential for the bacteria or their modified […]
Aurealis Therapeutics, a synthetic biology company developing ground-breaking cell and gene therapies for high unmet medical needs, has raised over $10 million through a Series A financing round co-led by Lynx Financial and TESI (Finnish […]
The community of microbes living in and on our bodies may be acting as a reservoir for antibiotic resistance, according to new research from the Earlham Institute and Quadram Institute in Norwich. The use of […]
IFF—a leading global player in the health and wellbeing industry—today reveals it has achieved the successful production of a strict anaerobic ‘next generation’ probiotic strain at industrial scale. The remarkable milestone demonstrates IFF’s unique capabilities […]
Pragma Bio, the technology-enabled platform for drug discovery formerly known as VastBiome, announced it has raised an additional $10 million in equity to continue its development of proprietary methods in genomic sequencing, artificial intelligence and […]
Not all probiotics are created equal. In a new study, researchers found that certain enzymes within a class known as bile salt hydrolases (BSHs) can restrict Clostridioides difficile (C. diff.) colonization by both altering existing bile acids and […]